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Abstract
The role of hydrogen sulfide (H2S) in inflammation remains unclear with both pro- and anti-inflammatory actions of this gas described. We have
now assessed the effect of GYY4137 (a slow-releasing H2S donor) on lipopolysaccharide (LPS)-evoked release of inflammatory mediators from
human synoviocytes (HFLS) and articular chondrocytes (HAC) in vitro. We have also examined the effect of GYY4137 in a complete Freund’s
adjuvant (CFA) model of acute joint inflammation in the mouse. GYY4137 (0.1–0.5 mM) decreased LPS-induced production of nitrite (NO2
),
PGE2, TNF-a and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygen-
ase-2 (COX-2) and reduced LPS-induced NF-jB activation in vitro. Using recombinant human enzymes, GYY4137 inhibited the activity of COX-
2, iNOS and TNF-a converting enzyme (TACE). In the CFA-treated mouse, GYY4137 (50 mg/kg, i.p.) injected 1 hr prior to CFA increased knee
joint swelling while an anti-inflammatory effect, as demonstrated by reduced synovial fluid myeloperoxidase (MPO) and N-acetyl-b-D-glucosa-
minidase (NAG) activity and decreased TNF-a, IL-1b, IL-6 and IL-8 concentration, was apparent when GYY4137 was injected 6 hrs after CFA.
GYY4137 was also anti-inflammatory when given 18 hrs after CFA. Thus, although GYY4137 consistently reduced the generation of pro-inflam-
matory mediators from human joint cells in vitro, its effect on acute joint inflammation in vivo depended on the timing of administration.
Keywords: hydrogen sulfide GYY4137 inflammation synoviocyte cytokinesmyeloperoxidase 
lipopolysaccharide Freund’s adjuvant COX-2 TNF-alpha converting enzyme
Introduction
Hydrogen sulfide (H2S) is produced in mammalian tissues from the
amino acids cysteine and homocysteine by the pyridoxal-5′-
phosphate (PLP)-dependent enzymes, cystathionine-c-lyase (CSE;
E.C. 4.4.1.1), cystathionine-b-synthetase (CBS; E.C. 4.2.1.22) and
3-mercaptopyruvate sulfurtransferase (3-MST; EC 2.8.1.2; reviewed
in [1, 2]). Despite extensive study, the part played by H2S in
inflammation remains unclear [3]. We demonstrated some years
ago that parenteral injection of the ‘fast-releasing’ H2S donor,
sodium hydrosulfide (NaSH), caused tissue inflammation in the
mouse as evidenced by increased organ myeloperoxidase (MPO)
activity following tissue neutrophil infiltration and the associated
rise in plasma levels of pro-inflammatory cytokines such as TNF-a
[4]. In addition, NaSH incresed leucocyte rolling/adhesion in the
mesenteric microcirculation as well as neutrophil migration in mice
with sepsis induced by caecal ligation and puncture [5]. Moreover,
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plasma H2S concentrations, tissue H2S synthesizing activity and
CSE expression were all elevated in a number of animal models of
inflammation (e.g. endotoxic, septic and haemorrhagic shock, pan-
creatitis, carrageenan-evoked hindpaw oedema; [4, 6–8]) which
together are strongly suggestive of a pro-inflammatory role for
H2S.
However, it is possible that the elevation of vascular and tissue
production of H2S observed in animal models of inflammation
may equally reflect an endogenous attempt to overcome, control
or resolve inflammation rather than potentiate or drive the
inflammatory response [1, 3]. More recent studies have shown
that, depending on the experimental conditions, H2S can also exert
prominent anti-inflammatory effects [3, 9]. For example, an H2S-
releasing derivative of diclofenac (c.f. diclofenac alone) exhibited
enhanced anti-inflammatory activity in endotoxic shock and against
carrageenan-induced hindpaw swelling [10, 11]. The slow-releas-
ing, water-soluble H2S donor, GYY4137, has also been shown to
be anti-inflammatory in a mouse model of endotoxic shock [12]
by mechanisms which include reducing macrophage generation of
pro-inflammatory mediators such as nitric oxide (•NO) and PGE2
[12, 13] and the promotion of phagocytosis [14]. GYY4137 also
inhibited IL-8 secretion and cell proliferation in primary human
airway smooth muscle cells [15] and stimulated the synthesis of
the anti-inflammatory chemokine IL-10 in rat plasma during sepsis
[12], albeit through undefined signalling pathways. H2S has also
been reported to promote ulcer healing [16], reduce lung injury
due to smoke inhalation [17] and decrease carrageenan-induced
hindpaw oedema [18] in the rat. Moreover, NaSH reduced
leucocyte infiltration in an air pouch model [18], and is
cardioprotective in pigs subjected to ischaemia reperfusion, most
likely by reducing formation of pro-inflammatory cytokines such as
TNF-a, IL-6 and IL-8 [19]. Thus, the literature is replete with con-
flicting evidence indicating that H2S can be both pro- and anti-
inflammatory [1, 3].
There have been few published reports of the role of H2S in
acute joint inflammation. Human cartilage cells are capable of
synthesizing H2S as part of an acute response to pro-inflamma-
tory mediators such as TNF-a, IL-6, IL-1b and bacterial lipopoly-
saccharide (LPS) and cytokine-induced H2S synthesis has been
proposed as a mechanism to protect joint cells from oxidative
injury [20]. Synovial fluid (SF) aspirated from the knee joints of
patients with inflammatory joint diseases in reactive [21, 22] and
psoriatic arthritides [3] contained higher concentrations of H2S
than paired plasma samples of SF from age-matched patients
with osteoarthritis. Using an animal model of acute monoarthritis
viz. intra-articular injection of kaolin/carrageenan into the knee
joint of mice [23], intra-articular sodium sulfide (Na2S) adminis-
tration caused a dose-dependent reduction in synovial leucocyte
adherence and an increase in leucocyte velocity, indicative of an
anti-inflammatory effect. We report here studies to probe the
effect of H2S on inflammatory mediator formation in cultured
synoviocytes in vitro and in an animal model of acute joint
inflammation in vivo using a slow-releasing H2S donor,
GYY4137.
Materials and Methods
Reagents
GYY4137 was synthesized in-house as described in [13, 24]. PPM-18
and NS-398 were purchased from Calbiochem Ltd. (Merck, Feltham, UK).
The following were purchased from R&D Systems Inc. (Minneapolis,
USA): ELISAs for COX-2, iNOS, TNF-a and IL-6, human recombinant
tumour necrosis factor–alpha-converting enzyme (TACE) and fluorogenic
TACE substrate Mca-Pro-Leu-Ala-Gln-Ala-Val-DPA-Arg-Ser-Ser-Ser-Arg-
NH2. PGE2 ELISA, COX-2 and NOS Activity Assay kits were purchased
from Caymen Chemicals (Ann Arbor, MI, USA). The NF-jB activation
ELISA was purchased from Active Motif (Carlsbad, CA, USA). Arginine
L-[14C(U)] (#NEC267E050UC) was purchased from Perkin Elmer
(Cambridgeshire, England). Human recombinant TNF-a, IFN-c and IL-1b
were purchased from PeproTech (Rocky Hill, NJ, USA). Rabbit monoclo-
nal antibodies to IjB-a and phosphor-IjB-a (Ser32) were purchased from
Cell Signalling Technology (Danvers, MA, USA). Rabbit polyclonal anti-
bodies to TACE and TACE/ADAM17 Activation Site were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Abcam (Cambridge,
England) respectively. All other chemicals and kits including lipopolysac-
charide (LPS; E. coli 0127:B8), anti-rabbit and anti-mouse IgG secondary
antibodies, mouse anti-tubulin monoclonal antibodies and 1400W were
purchased from Sigma-Aldrich (Poole, Dorset, England).
Cell culture and exposure of cells to
inflammatory mediators
Normal human fibroblast-like synoviocytes (HFLS) were purchased
from Cell Applications Ltd. (Salisbury, England) and cultured in
Dulbecco’s Modified Eagles Medium (DMEM) containing glutamine
(2 mM), penicillin (100 units/ml), streptomycin (100 lg/ml), ampho-
tericin B (0.25 lg/ml) and foetal bovine serum (10% v/v) and incu-
bated in a humidified incubator with 5% CO2/95% air at 37°C.
Human articular chondrocytes (HAC) were purchased from Cell
Applications and cultured in monolayer in chondrocyte growth med-
ium (Cell Applications) as described [20]. Prior to the addition of
LPS, HFLS and HAC were seeded overnight in 24-well plates (Grein-
er; 0.25 9 106 cells/well) then washed once with phosphate-buffered
saline (PBS) and media replaced with either serum-free media (i.e.
unstimulated samples) or serum-free media containing either bacte-
rial LPS (E. coli 0127:B8; 10 lg/ml) or a mixture of cytokines
(10 ng/ml each of TNF-a and IFN-c with 1 ng/ml IL-1b) in the pres-
ence or absence of GYY4137 (100–500 lM). In some experiments,
cells were additionally pre-incubated (1 hr) with either NS-398 (COX-
2 inhibitor, 10 lM; [25]), 1400W (iNOS inhibitor, 10 lM; [26]) or
PPM-18 (inhibitor of NF-jB activation, 10 lM, [27]) prior to addition
of GYY4137/LPS. Thereafter, cells were incubated for a further
24 hrs and the culture medium collected and centrifuged (2 min.,
full speed) in a microcentrifuge. The resulting cell pellet was pro-
cessed for COX-2 and iNOS ELISA according to the manufacturer’s
instructions and Western blotting (TACE, IjBa, phosphor-IjBa) and
the aspirate removed for cytokine, NO2
, IL-6, TNF-a and PGE2 anal-
ysis [13]. PGE2 levels in culture media were determined using a
PGE2 enzyme immunoassay kit (Cayman, Ann Arbor, MI, USA). TNF-
a and IL-6 were assayed by ELISA according to the manufacturer’s
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instructions (R&D Systems) [13]. NO2
 was determined by Griess
assay in cell culture media as described elsewhere [28]. Cell viability
assessed after GYY4137 treatment using MTT assay [20] and control
experiments showed that concentrations of up to 5 mM GYY4137
did not induce significant cytotoxicity in either HFLS or HAC in this
assay. For analysis of the activation of the transcription factor NF-
jB using a commercial ELISA (ActiveMotif), the above incubation
conditions were repeated using cells seeded overnight in T-75 flasks
(3.5 9 106 cells/flask). Nuclear and cytoplasmic fractions were then
prepared according to the manufacturer’s instructions [9, 13]. Total
IjB levels and IjB phosphorylation were determined by Western
blotting using antibodies from Cell Signalling Technology.
A B
C D
E F
Fig. 1 Effect of GYY4137 on LPS- and cytokine-induced synthesis of pro-inflammatory mediators in human synoviocytes (HFLS). HFLS were treated
with GYY4137 at the concentrations stated for 1 or 5 hrs post-LPS (10 lg/ml) stimulation for 18 hrs. After this time, cell culture media were
collected and analysed for (A) PGE2, (B) TNF-a and (C) IL-6 by commercial ELISA and (D)
●NO (measured as NO2
) determined by Griess assay.
(E–F) Effect of GYY4137 on cytokine cocktail (comprising of 10 ng/ml TNF-a and IFN-c and 1 ng/ml, IL-1b)-stimulated NO2- (E) and PGE2 (F). The
iNOS inhibitor (1400W; 100 lM) was added for 1 hr prior to LPS stimulation. Data shown are mean  SEM of at least three separate determina-
tions. *P < 0.05 c.f. LPS/cytokine-stimulated cells.
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Effect of GYY4137 on isolated pro-inflammatory
enzymes
To determine whether H2S inhibited the catalytic activity of pro-inflam-
matory enzymes directly, we exposed TNF-a converting enzyme (TACE),
COX-2 and iNOS directly to GYY4137. TACE activity was determined
using recombinant human TACE enzyme (R&D Systems) and the fluoro-
genic TACE substrate Mca-Pro-Leu-Ala-Gln-Ala-Val-DPA-Arg-Ser-Ser-
Ser-Arg-NH2 (R&D Systems). GYY4137 and Na2S were prepared at
twice the final concentration in assay buffer and the respective H2S
donor or assay buffer control added to the wells of a black 96-well plate
(Greiner Bio-One, Gloucestershire, UK). Recombinant human TACE
(30 ng/ml final concentration) was added to each sample well and a
recombinant human TACE standard curve (7.5–60 ng/ml final concen-
tration) added to the plate. The plate was incubated for 16 hrs at 20°C.
Fluorogenic substrate was then added (7.5 lM final concentration) and
the plate protected from light and incubated for 4 hrs at 37°C. Fluores-
cence was measured on a SpectraMax M2e microplate reader (Molecu-
lar Devices, Wokingham, UK) using excitation and emission
wavelengths of 320 and 405 nm respectively.
COX-2 activity was determined using the COX Inhibitor Screening
Assay Kit (Cayman Chemicals), according to the manufacturer’s instruc-
tions. GYY4137, Na2S and DuP697 (COX-2 inhibitor; Cayman) were pre-
pared in reaction buffer and reaction tubes set up containing
recombinant COX-2, haem and either H2S donors, DuP697 or reaction
buffer only control. Reaction tubes were pre-incubated at 37°C for 1 hr,
after which arachidonic acid substrate was added and the tubes incu-
bated for a further 2 min. The reaction was stopped by the addition of
HCl and the PGH2 produced in the reaction converted to PGF2a by the
addition of stannous chloride. PGF2a levels were measured by competi-
tive enzyme immunoassay using a 1:4000 dilution of the samples in EIA
buffer. Absorbance at 405 nm was measured on a SpectraMax M2e
microplate reader (Molecular Devices).
Nitric oxide synthase activity was determined using the NOS Activity
Assay Kit (Caymen Chemicals, Ann Arbor, MI, USA) and L-14C arginine
and human recombinant NOS in the presence or absence of GYY4137,
Na2S or L-N(G) nitroarginine (L-NNA; iNOS inhibitor supplied with the
NOS Activity Kit). The reaction tubes were incubated at 37°C for 1 hr,
after which the reaction was stopped by the addition of stop buffer.
Samples were processed according to the manufacturer’s instructions
and the amount of radioactive L-citrulline produced measured on a LS
6500 Multi-Purpose Scintillation Counter (Beckman Coulter, High Wy-
combe, UK).
Induction of acute joint inflammation in the
mouse
Animals were treated in accordance with the Animals (Scientific Proce-
dures) Act 1986 (UK). Male CD1 mice (25–35 g) were used essentially as
A B
C D
Fig. 2 Effect of GYY4137 on LPS- and cytokine-induced synthesis of pro-inflammatory mediators in human articular chondrocytes (HAC). HAC were
treated with GYY4137 at the concentrations stated for 1 or 5 hrs post-LPS (10 lg/ml) stimulation for 18 hrs. After this time, cell culture media
were collected and analysed for (A) PGE2, (B) TNF-a and (C) IL-6 by commercial ELISA and (D)
•NO (measured as NO2
) determined by Griess
assay. Inhibitors of COX-2 (NS-398; 10 lM) and iNOS (1400W, 100 lM) were added for 1 hr prior to LPS stimulation. Data shown are
mean  SEM of at least three separate experiments. *P < 0.05 c.f. LPS-stimulated cells.
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described previously [29]. Mice were briefly anaesthetized with isofluorane
(2%) and injected intra-articular (30-gauge needle) into one rear knee joint
(chosen at random) with complete Freund’s adjuvant (CFA, 10 lg) in a vol-
ume of 10 ll. The other rear knee joint was injected at the same time with
an equal volume of pyrogen-free saline as control. Mice were treated with
GYY4137 (50 mg/kg, i.p.) or an appropriate volume of vehicle (saline)
either 1 hr before or 6 or 18 hrs after CFA injection and all animals were
killed at 24 hr. The diameter of both knee joints was measured under isoflu-
A B
C D
E F
Fig. 3 Effect of GYY4137 on LPS-induced expression of COX-2, iNOS and TNF-a-converting enzyme (TACE) expression and activity in human synovi-
ocytes and human articular chondrocytes. HAC and HFLS were treated with GYY4137 at the concentrations stated for 1 hr prior to LPS (10 lg/ml)
stimulation for 18 hr. After this time, cells were lysed and levels of COX-2 (A) and iNOS (B) determined by commercial ELISA. (C) Expression of
pre- and mature TACE was determined in HFLS by Western blotting after 24 hr. (D–F) Effects of GYY4137 on isolated human recombinant COX-2
(D), iNOS (E) and (F) TACE activity. Recombinant enzyme activities are expressed as % control enzyme activity after 1 hr (iNOS and COX-2) and
4 hr (TACE). GYY4137 was added at the concentrations stated and enzyme activity determined. DuP697 (1 lM) was used as a positive control for
COX-2 activity and L-NNA (supplied with the NOS activity kit; 100 lM) as positive control for iNOS activity. Western blots are representative of three
separate determinations and data shown are mean  SEM of at least three separate experiments. *P < 0.05 c.f. LPS-stimulated cells.
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orane anaesthesia using calipers (Mitutoyo Inc., Andover, Hamps, UK) both
before and at the end of the experiment. The measurements taken were
used as an index of knee swelling. All experiments were performed blind in
that the investigator was not aware which animals were drug or vehicle
injected.
At the end of the experiment, animals were anaesthetized and synovial
fluid (~50 ll in heparinized saline, 5 U/ml) was aspirated from each knee
joint. Aliquots of synovial fluid were assayed immediately for H2S or stored
at 80°C. MPO activity, reflecting the presence of neutrophils, was deter-
mined as described previously [4]. The presence of monocytes/macrophag-
es in synovial fluid was assessed using the N-acetyl-b-D-glucosaminidase
(NAG) assay as described elsewhere [30]. Cytokine (TNF-a, IL-1b, IL-6,
IL-8) concentration were determined by ELISA using commercially available
kits (R&D Systems) according to the manufacturer’s instructions. Synovial
fluid H2S levels were determined by zinc-trap spectrophotometry [4, 22].
For assessment of drug effects on knee joint structure, tissues from
arthritic and non-arthritic control and GYY4137-treated mice were rap-
idly removed after death, immediately fixed in 10% v/v phosphate-buf-
fered formalin (pH 7.4) for 48 hrs and subsequently embedded in
paraffin, fixed as above for 72 hrs and then decalcified in 5% v/v buf-
fered formic acid for 14 days. Sections (4 lm) were cut using a micro-
tome and stained with haematoxylin and eosin. Sections were thereafter
examined by light microscopy at either 2009 or 6009 magnification.
Statistical analysis
Data are expressed as mean  SEM with the number of independent
observations shown in parenthesis. Multiple comparisons were made by
ANOVA followed by post hoc Tukey test. Statistical significance of the dif-
ference between means was set at P < 0.05.
Results
Effects of GYY4137 on HFLS and HAC
Treatment of HFLS (Fig. 1) or HAC (Fig. 2) with LPS signifi-
cantly increased the levels of PGE2 [A], TNF-a [B], IL-6 [C]
A B
C D
Fig. 4 Effect of GYY4137 on LPS-induced NF-jB activation and activity. HFLS (A) and HAC (B) were treated with GYY4137 or an inhibitor of NF-kB
activation (PPM-18) at the concentrations stated for 1 hr before or 4 hrs post-LPS (10 lg/ml) stimulation for 18 hrs. After this time, nuclear
extracts were prepared and p65-NF-jB DNA binding determined by commercial ELISA. (C) Time course of cytokine cocktail (10 ng/ml each of TNF-
a and IFN-c with 1 ng/ml IL-1b) induced IjBa degradation and phosphor-IjBa phosphorylation in HFLS (D) Effects of GYY4137 added 1 hr prior
or 1 hr post-cytokine cocktail stimulation on IjBa degradation and phosphor-IjBa phosphorylation in HFLS. Data shown are mean  SEM of at
least three separate experiments. *P < 0.05 c.f. LPS-stimulated cells.
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and •NO (measured as NO2
) [D] in culture supernatant of both
joint cell types. Treatment of HFLS (Fig. 1A–D) or HAC (Fig. 2A
–D) with GYY4137 (100–500 lM) for 1 hr prior to stimulation
significantly reduced the levels of pro-inflammatory mediators
in culture supernatant. Similarly, GYY4137 (>100 lM)
significantly inhibited the increase in ●NO (Fig. 1E) and PGE2
(Fig. 1F) levels induced by a cocktail of TNF-a (10 ng/ml),
interleukin-1 beta (IL-1b; 1 ng/ml) and interferon-gamma (IFN-
c; 10 ng/ml).
In preliminary experiments (data not shown), LPS induced an
increase in COX-2 and iNOS enzyme levels in a time-dependent
manner in both HFLS and HAC with significant increases of each
enzyme observed at 5 hrs post-LPS treatment. To determine
whether GYY4137 inhibited the activity of these enzymes (e.g.
PGE2 and
•NO synthesis) once COX-2 and iNOS levels were
induced, cells were stimulated with LPS for 5 hrs, followed by
treatment with GYY4137 for a further 18 hrs. GYY4137 signifi-
cantly reduced the concentration of pro-inflammatory mediators
when added to HFLS (Fig. 1) or HAC (Fig. 2) 5 hrs post-LPS-treat-
ment albeit to a lesser extent than selective iNOS inhibitor
(1400W).
To determine whether GYY4137 affected the levels of COX-2 or
iNOS enzymes, intracellular levels of these proteins were deter-
mined in LPS-treated cells by ELISA. Treatment of HFLS or HAC
with GYY4137 for 1 hr prior to LPS significantly reduced LPS-
induced COX-2 (Fig. 3A) and iNOS (Fig. 3B) protein levels in addi-
tion to reducing PGE2 and NO2
 levels. Although treatment of HFLS
with a cocktail of cytokines (TNF-a, IL-1b and IFN-c) induced an
increase in the levels of TACE protein (Fig. 3C), the level of this
enzyme was unaffected by GYY4137. To examine further the possi-
bility that the attenuation of LPS-stimulated increases in PGE2,
●NO
and TNF-a (Figs 1 and 2) were due to an inhibitory effect of
GYY4137 on COX-2, iNOS and TACE activity, respectively, we incu-
bated human recombinant COX-2, iNOS and TACE with GYY4137
and determined residual catalytic activity. GYY4137 and Na2S
significantly inhibited COX-2, iNOS and TACE activity (Fig. 3D–F),
respectively, suggesting that H2S could directly inhibit enzyme
activity and consequently cellular synthesis/secretion of PGE2,
NO2
 and TNF-a which is independent of any effect of this drug on
COX-2 or iNOS protein levels.
We next examined the effects of GYY4137 on NF-jB activation
in HFLS and HAC. Treatment of cells with GYY4137 for 1 hr prior
to LPS stimulation significantly reduced NF-jB activation in HFLS
(Fig. 4A) and HAC (Fig. 4B). Significant inhibition of NF-jB activa-
tion was also observed in HFLS (Fig. 4A) and HAC (Fig. 4B) when
GYY4137 was added to cells 4 hrs post-LPS treatment although
this inhibitory effect was much less marked. This effect of
GYY4137 was mimicked by PPM-18 (classical inhibitor of NF-jB
activation) although GYY4137 was less effective. Although treat-
ment of HFLS with a cytokine cocktail (containing 10 ng/ml each
of TNF-a and IFN-c with 1 ng/ml IL-1b) for up to 2 hrs resulted
in IjBa phosphorylation and degradation of IjBa (Fig. 4C), further
Western blotting analysis (Fig. 4D) revealed that GYY4137 did not
reduce the cytokine cocktail-induced IjBa degradation or phos-
phorylation.
Effects of GYY4137 in a murine model of acute
joint inflammation
Intra-articular injection of CFA in the mouse caused significant knee
joint swelling measured 24 hrs thereafter. In contrast, intra-articular
injection of an equivalent volume of saline into the contralateral knee
joint did not cause joint swelling (Fig. 5A). Furthermore, under these
experimental conditions, H2S concentration was significantly higher
in synovial fluid from CFA-injected (i.e. swollen) as compared with
saline-injected (i.e. unswollen), contra lateral knee joints (Fig. 5B).
GYY4137 (50 mg/kg, i.p.) or saline was administered to mice
either 1 hr before or 6 or 18 hrs after intra-articular injection of CFA.
In all cases, animals were killed 24 hrs after CFA injection. Saline did
not cause knee joint swelling at any time-point of injection (data not
shown). Pre-treatment (1 hr) of animals with GYY4137 resulted in a
significant increase in CFA-induced knee joint swelling (Fig. 6A) with-
out any change in synovial fluid MPO activity (Fig. 6B). In contrast,
injection of GYY4137 18 hrs after CFA reduced knee joint swelling
(Fig. 6C) and also decreased synovial fluid MPO activity (Fig. 6D).
Administration of GYY4137 6 hrs after intra-articular injection of CFA
did not affect knee joint diameter (Fig. 7A), but did significantly
reduce synovial fluid MPO activity (Fig. 7B) and NAG (Fig. 7C), TNF-a
A
B
Fig. 5 Effects of intra-articular injection of complete Freund’s adjuvant
(CFA) on knee swelling and synovial fluid levels of H2S. CD1 mice were
injected with CFA (10 lg in 10 ll) or vehicle (saline) and the effect on
knee measured at 24 hr (A). (B) Effect of CFA treatment on knee joint
synovial fluid H2S determined by zinc-trap spectrophotometry. Data
show mean  SEM, n = 6, *P < 0.05 c.f. saline-injected contralateral
knee joint.
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(Fig. 7D), IL-1b (Fig. 7E), IL-6 (Fig. 7F) and IL-8 (Fig. 7G) concentra-
tions. Intriguingly, despite the apparent inability of GYY4137 adminis-
tered 6 hrs after CFA injection to affect knee joint swelling, evidence
of reduced neutrophil infiltration and inflammation was also apparent
upon histological examination of treated knee joints (Fig. 8).
Discussion
Hydrogen sulfide has been proposed to be a novel mediator of inflam-
mation. However, the literature is complex and diametrically opposite
views on the role(s) of this gas in inflammation have been expressed.
We previously proposed that these conflicting observations may be
due, at least in part, to the manner in which cells/animals are exposed
to H2S [1–3, 12]. For example, the vast majority of studies examining
the pharmacological effects of H2S have used sulfide salts (e.g. Na2S
and NaSH), often at millimolar concentrations, as the source of H2S,
and have generally concluded that H2S is pro-inflammatory (reviewed
in [1, 3]). These sulfide salts generate an instantaneous bolus of H2S
(as well as HS and Na+) which dissipates within seconds whereas
endogenous H2S synthesis via CSE and/or CBS is slow and sustained
[12, 13, 24, 31, 32]. As such it is less likely that, in vivo, cells would
be exposed to a bolus of concentrated H2S, as generated with Na2S
or NaSH (or similar sulfide salts), and more likely that slow-releasing
H2S donors such as GYY4137 better reflect the role of cell-derived
H2S in the inflammatory response. Interestingly, unlike sulfide salts,
slow-releasing H2S donors such as GYY4137 and H2S-releasing
derivatives of diclofenac or aspirin are generally anti-inflammatory [1
–3].
In our current study, GYY4137 caused a range of biochemical
effects in cultured synoviocytes (HFLS) and chondrocytes (HAC)
in vitro which were commensurate with an anti-inflammatory effect of
this compound in vivo. Thus, GYY4137 produced a concentration-
dependent inhibition of ●NO (measured as nitrite), PGE2, TNF-a and
IL-6 production by intact cells. Moreover, in separate experi-
ments, GYY4137 inhibited the catalytic activity of both iNOS and
COX-2 in vitro. Although Na2S has previously been shown to inhibit
iNOS activity [33,34], a direct effect of H2S on COX-2 activity has not
previously been reported. It seems likely that the molecular target for
H2S in both enzymes is the haem group [35]. In addition, GYY4137
also reduced iNOS and COX-2 protein levels. NF-jB plays a key part
in the transcriptional regulation of both iNOS and COX-2 and is thus a
likely target for H2S. Inhibition of NF-jB DNA-binding activity by
GYY4137 has been observed in isolated rat neutrophils [12], mouse
macrophages [13] and in vivo in a murine model of endotoxic shock
[12]. Moreover, slow-releasing H2S donor derivatives of diclofenac
A B
C D
Fig. 6 Effects of GYY4137 on knee joint swelling and synovial FLUID MPO activity in CFA-induced acute joint inflammation. (A) GYY4137 (50 mg/kg,
i.p.) or saline (0.5 ml/kg, i.p.) was administered to mice either 1 hr before (A and B) or 18 hrs (C and D) after intra-articular injection of CFA or sal-
ine. (A and C) joint swelling. (B and D) Synovial MPO activity. Mice were killed 24 hrs after CFA or saline injection. Data shown mean  SEM,
n = 6, *P < 0.05 c.f. CFA-injected mice receiving saline.
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[10, 11, 16, 36] and aspirin [37] also inhibit NF-jB activation.
Recently, H2S-derived either from GYY4137 or from NaSH has been
shown to sulfhydrate the p65 subunit of NF-jB at the cysteine38 resi-
due, resulting in the formation of a perthiol group on cysteine38 and
modulation of DNA-binding activity [38]. In this study, GYY4137 did
not affect IjBa degradation or IjBa phosphorylation but did inhibit
NF-jB DNA-binding activity suggesting this as a likely mechanism of
action of this molecule in synovial cells.
An additional novel feature of this study is the finding that
GYY4137 reduced TNF-a formation when added to HFLS or HAC
either 1 or 6 hrs after LPS stimulation. GYY4137 did not affect
intracellular levels of TACE protein or activation in these cells sug-
gesting that the reduction in LPS-evoked synthesis of TNF-a is
secondary to inhibition of TACE catalytic activity rather than modu-
lation of TACE enzyme levels. Interestingly, TACE is a zinc-contain-
ing metalloproteinase which converts membrane-bound pro-TNF-a
to mature and soluble TNF-a [39]. The zinc centres of other pro-
teinases such as angiotension converting enzyme (ACE) are also
targeted by H2S (albeit from NaSH; >200 lM) and account for the
inhibitory effect on ACE activity in human umbilical vein endothelial
cells [40]. As H2S has a high affinity for zinc, a property widely
exploited for the measurement of H2S levels and tissue synthesis
[2], it is possible that the zinc component of TACE is a target for
H2S in these cells. Thus, this effect of GYY4137 on TACE activity
may account, at least in part, for the inhibition of LPS-induced
TNF-a synthesis in HFLS and HAC.
A
D
E
F
G
B
C
Fig. 7 Effects of GYY4137 on CFA-induced joint inflammation. CFA (10 lg in 10 ll) or vehicle (saline) were injected into the knee joints of CD1 mice
and GYY4137 (50 mg/kg, i.p.) or saline (0.5 ml/kg, i.p.) administered 1 or 6 hrs thereafter. (A) knee joint swelling, (B) MPO activity (C) NAG con-
centration measured both 1 and 6 hrs after drug/vehicle injection. Synovial fluid levels of (D) TNF-a, (E) IL-6, (F) IL-1b and (G) IL-8 were deter-
mined in CFA-injected animals injected 6 hrs after drug/vehicle injection. All mice were killed 24 hrs after CFA or saline injection. Data show
mean  SEM, n = 6–8, *P < 0.05 c.f. CFA-injected mice receiving saline.
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From the foregoing it is obvious that the predominant
effect of GYY4137 in cultured HFLS and HAC in vitro is anti-
inflammatory. Thus, it was of interest to determine whether
GYY4137 also reduced inflammation in a mouse model of
inflammation.
Complete Freund’s adjuvant injection into the knee joint of mice
resulted in joint swelling and a significant elevation in synovial fluid
H2S levels, consistent with a previous study showing increased
synovial fluid H2S levels in patients with inflammatory joint dis-
eases compared with paired plasma and synovial fluid from osteo-
arthritis patients [3, 22]. Previous studies in mice have shown
increased CSE mRNA levels in the liver and kidney following induc-
tion of acute inflammation with LPS, as well as increased CSE
enzyme levels in liver following stimulation with TNF-a [4, 38].
Also, in vitro studies showed induction of CSE, but not CBS, fol-
lowing stimulation with pro-inflammatory cytokines (TNF-a, IL-6
and IL-1b) or LPS in human articular chondrocytes and peritoneal
macrophages [20, 38]. Several studies indicate that the induction
of CSE is a key factor towards the increased H2S levels observed
in acute inflammation. For instance, carrageenan-induced H2S syn-
thesizing activity in rat hindpaw was significantly reduced following
pre-treatment with the CSE inhibitor PAG [41], as were synovial
fluid H2S levels [42]. Also, a significant reduction in the TNF-a-
induced rise in liver H2S levels was observed in CSE
/ mice and
peritoneal macrophages derived from CSE / mice [38]. However,
the precise roles of enzyme-dependent and enzyme-independent
mechanisms of H2S synthesis in acute joint inflammation remain to
be defined.
Intriguingly, the effect of GYY4137 in vivo depended on the tim-
ing of its injection. For example, when administered 1 hr before
intra-articular CFA (i.e. ‘prophylactically’) GYY4137 was not anti-
inflammatory but indeed was pro-inflammatory i.e. increasing knee
joint swelling measured at 24 hr. However, injection of GYY4137
either 6 or 18 hrs after CFA administration (i.e. ‘therapeutically’)
was anti-inflammatory. These data suggest that GYY4137-derived
H2S exerts different effects at different stages of the inflammatory
response. The pro-inflammatory effect of GYY4137, which is appar-
ent in the early stages of an inflammatory response, is likely due to
H2S-mediated vasodilatation [12, 24] causing augmented joint
blood flow and vascular permeability and thereby exacerbating knee
joint swelling. The observation that MPO activity (indicative of the
presence of neutrophils) was unchanged in synovial fluid from ani-
mals so treated suggests that neutrophils were not involved in the
pro-inflammatory effect of GYY4137 when given prophylactically.
Interestingly, intra-articular injection of Na2S into the mouse knee
joint reportedly has the opposite effect i.e. synovial microvessel
constriction coupled to a fall in synovial blood flow [23]. The rea-
sons for the discrepant data are not clear but differences between
the two studies in terms of both the inflammatory agent (carra-
geenan/kaolin c.f. CFA) and the H2S donor (Na2S c.f. GYY4137)
used may play a part.
In sharp contrast, GYY4137 administered either 6 or 18 hrs
after CFA injection, when knee joint swelling had become estab-
lished, exhibited anti-inflammatory activity. At 6 hr, synovial fluid
MPO activity, NAG (a marker of monocytes/macrophages) and
cytokine (TNF-a, IL-1b, IL-6, IL-8) concentrations were reduced by
GYY4137 treatment thereby mirroring its effect on synovial cells in
culture. GYY4137 has recently been shown to inhibit IL-8 formation
in vitro [15]. Overall, GYY4137 administered ‘therapeutically’ (i.e.
after CFA injection into the knee joint) exhibited anti-inflammatory
activity most likely by mechanisms which include an effect on leu-
cocyte recruitment and inhibition of pro-inflammatory mediator
production.
In summary, we show here that GYY4137, a slow-releasing
H2S donor, elicits anti-inflammatory activity in LPS- and cytokine-
challenged HFLS and HAC as demonstrated by the ability to
reduce the levels of pro-inflammatory mediators and cytokines and
to ameliorate the induction of pro-inflammatory iNOS and COX-2.
In contrast, GYY4137 can exhibit either pro- or anti-inflammatory
activity in a mouse model of acute joint inflammation depending
on the timing of its administration. Thus, H2S affects inflammation
in a number of ways including localized vasodilatation and
changes in vascular permeability as well as inhibition of mediator
release from inflammatory cells. Not only is the anti-inflammatory
effect of H2S determined by the choice of donor (i.e. ‘fast’ versus
‘slow’ releasing agent) but also by the timing of donor administra-
tion. The anti-inflammatory effects of GYY4137 observed in this
study were at concentrations of GYY4137 ranging from 100 to
A
B C
Fig. 8 Histological assessment of the effects of GYY4137 on CFA-
induced knee joint inflammation. GYY4137 (50 mg/kg, i.p.) or vehicle
control saline (0.5 ml/kg, i.p.) was administered to mice 6 hrs after
intra-articular injection of CFA or saline and killed 24 hrs thereafter. Fig-
ure shows photomicrographs of knee joint sections (2009) and inserts
show intra-articular (marked with *) and peri-articular space of knee
joints (6009) representative of three separate animals. In these inserts,
please note A) the absence of inflammatory cells in the intra-articular
space of the non-inflamed joint; B) the presence of florid inflammation
in the same space of a CFA-treated animal; and C) the reduction in
inflammation achieved in the same space of the GYY4137-CFA-treated
animal.
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500 lM. The rate of H2S production from this molecule is
estimated to be ~1 lM/hr so much less than 100–500 lM H2S
was generated. These concentrations of GYY4137 had no effect on
cell viability under the conditions used in this study (data not
shown), but could potentially introduce side effects in therapeutic
applications. Therefore, both the timing and effective concentration
of H2S donor should be borne in mind when considering the
development of novel anti-inflammatory agents based on the
principle of H2S donation.
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